The latest research, news, and more from GeoInvesting for Avita Medical, Inc. (RCEL) /companies/rcel_avita_medical__inc_/overview en-us Wed, 29 Apr 2026 18:23:53 GMT Wed, 29 Apr 2026 18:23:53 GMT 120 63336Thu, 22 May 2025 14:50:26 GMTAvita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022./companies/rcel_avita_medical__inc_/overview